Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A disease characterized by higher than normal platelet counts in the peripheral blood.
Biomarker and diagnostic research for thrombocytosis disease has been reported in the published literature.
9 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE3, 3 PHASE2, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06218628](https://clinicaltrials.gov/study/NCT06218628) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:51 PM UTC
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition |
PHASE1 |
Fox Chase Cancer Center |
RECRUITING |
[NCT06514807](https://clinicaltrials.gov/study/NCT06514807) | A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients | PHASE3 | AOP Orphan Pharmaceuticals AG | ACTIVE_NOT_RECRUITING |
[NCT07468916](https://clinicaltrials.gov/study/NCT07468916) | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia | PHASE2 | Jonsson Comprehensive Cancer Center | NOT_YET_RECRUITING |
[NCT06923670](https://clinicaltrials.gov/study/NCT06923670) | Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History | NA | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | NOT_YET_RECRUITING |
[NCT00722527](https://clinicaltrials.gov/study/NCT00722527) | Molecular Biology of Polycythemia and Thrombocytosis | — | University of Utah | RECRUITING |
123 publications have been identified in PubMed for thrombocytosis disease. Research spans Case Report / Case Series (33%), Epidemiology / Natural History (23%), and Clinical Trial Publication (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 40 | 33% |
Disease patterns and progression | 28 | 23% |
Clinical study results | 18 | 15% |
Laboratory research | 14 | 11% |
Research summaries | 12 | 10% |
Testing and diagnosis research | 6 | 5% |
Other research | 3 | 2% |
New treatment approaches | 2 | 2% |
Liu T (2026). [PMID: 41997843](https://pubmed.ncbi.nlm.nih.gov/41997843/). *Pediatr Neonatol*. [Diagnostic / Biomarker]
Kishimoto K (2026). [PMID: 41623254](https://pubmed.ncbi.nlm.nih.gov/41623254/). *The Journal of dermatology*. [Case Report / Case Series]
Yang W (2026). [PMID: 41770496](https://pubmed.ncbi.nlm.nih.gov/41770496/). *Discov Oncol*. [Basic Science / Preclinical]
Lê GN (2026). [PMID: 42207175](https://pubmed.ncbi.nlm.nih.gov/42207175/). *Br J Haematol*. [Review / Meta-Analysis]
Meydan Y (2026). [PMID: 42207481](https://pubmed.ncbi.nlm.nih.gov/42207481/). *Spine Deform*. [Epidemiology / Natural History]
Li Y (2026). [PMID: 41926906](https://pubmed.ncbi.nlm.nih.gov/41926906/). *Thromb Res*. [Basic Science / Preclinical]
Leongamornlert D (2026). [PMID: 42008361](https://pubmed.ncbi.nlm.nih.gov/42008361/). *Cancer Discov*. [Epidemiology / Natural History]
Zhang L (2026). [PMID: 42051695](https://pubmed.ncbi.nlm.nih.gov/42051695/). *Front Med (Lausanne)*. [Case Report / Case Series]
Delfino L (2026). [PMID: 41594233](https://pubmed.ncbi.nlm.nih.gov/41594233/). *Diagnostics (Basel, Switzerland)*. [Clinical Trial Publication]
Liu J (2026). [PMID: 42163868](https://pubmed.ncbi.nlm.nih.gov/42163868/). *Am J Cancer Res*. [Epidemiology / Natural History]